AnaptysBio (ANAB) AI Stock Analysis

AnaptysBio

(BMV:ANAB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitability and Revenue InflectionThe substantial improvement in revenue and profitability shows a meaningful earnings inflection versus prior loss-making periods. If the company can sustain collaboration economics and development progress, this stronger earnings base could support reinvestment and improve financial resilience over the next several quarters.

Negative Factors

Compressed Balance-Sheet CushionVery low equity relative to debt leaves less balance-sheet protection against earnings volatility or unexpected cash needs. The sharp increase in debt-to-equity from prior years may constrain financial flexibility and make the company more sensitive to setbacks in development or collaboration-related cash flows.

AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 1.44B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 7.2
Beta (1Y): -0.05
Revenue Growth: ―
EPS Growth: ―
Country: Mexico
Employees: 104
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete wh...

AnaptysBio Risk Analysis

AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Risks Related to Ownership of Our Common StockQ1, 2026

2.Risks Related to Our Recent SeparationQ1, 2026

3.Risks Related to Intellectual PropertyQ1, 2026

AnaptysBio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ANAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYME	59Neutral	$2.03B	-14.16	-72.07%	―	-69.78%	-106.07%
CRVS	54Neutral	$843.73M	-15.67	-36.15%	―	―	8.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CGEM	50Neutral	$967.25M	-4.46	-52.89%	―	―	3.56%
XNCR	47Neutral	$2.22B	-13.74	-28.66%	―	-28.56%	10.25%
CTMX	43Neutral	$509.88M	-5.20	-38.46%	―	-87.03%	-179.91%

* Healthcare Sector Average

Performance Comparison

MX:ANAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ANAB	AnaptysBio	668.00	88.00	15.17%
XNCR	Xencor Inc.	29.82	15.88	113.92%
CTMX	CytomX Therapeutics Inc.	2.34	-1.59	-40.46%
CRVS	Corvus Pharmaceuticals Inc.	10.03	2.35	30.60%
ZYME	Zymeworks	28.61	9.72	51.46%
CGEM	Cullinan Therapeutics Inc	15.03	7.22	92.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AnaptysBio AI Stock Analysis